SlideShare a Scribd company logo
1 of 89
Download to read offline
Molar pregnancy
Presented By
Nirsuba Gurung
Masters in nursing
Women health and development
 Gestational Trophoblastic disease
comprises a spectrum of interrelated
conditions originating from the placenta.
 Gestational trophoblastic disease is a
prolifirative disorder of trophoblastic cells
 It can be benign, premalignant or malignant
Classification of gestational Trophoblastic disease
WHO Classification
Malignant neoplasms
of various types of
trophoblats
Malformations of the
chorionic villi that are
predisposed to
develop trophoblastic
malignacies
Benign entities that
can be confused with
with these other
lesions
Choriocarcinoma
Complete
Hydatidiform moles
Placental site nodule
Exaggerated placental s
Epithilioid trophoblastic
tumors
Placental site
trophoblastic tumor Partial
Invasive
 Non-metastatic disease: confined to the
uterus
 Metastatic
 A- low risk-good prognosis
 B – high risk-poor prognosis
Low risk
 Disease present in less than 4 mooths
duration
 Initial serum hCG level < 40,000 IU/ml
 Metastasis limited to lung and vagina
 No prior chemotherapy
 No preceding term pregnancy
High risk
 Long duration of disease
 Initial serum hCG level > 40,000 IU/ml
 Brain or liver metastasis
 Failure of prior chemotherapy
 Following term pregnancy
Hydatidiform Mole
 Definition:
 In latin
"hydatid" means "drop of water”
"mole" means "spot”
 Pathologically,
Hydatidiform moles represents placentas with
abnormally developed chorionic villi (enlarged,
edematous and vesicular villi with variable
amounts of proliferative trophoblast)
Macroscopic of Hydatidiform
mole
Hydropic villi
Grapelike vesicles
filled clear material
usually 1 to 3cm
diameter
proliferation of the
trophoblast
Hydatidiform mole(molar
pregnancy)
 Molar pregnancy is an abnormal form
of pregnancy, wherein a non viable ,
fertilized egg implants in the uterus, and
thereby converts pregnancy process into
pathological ones.
 It is characterized by presence of
hyadatidiform moles.
It is an abnormal condition of the
placenta where there are partly
degenerative and partly proliferative
changes in the young chorionic
villi.
 These results in the formation of clusters
of small cysts of varying size
 It is regarded as a begin neoplasia of the
chorion with malignant potential
INCIDENCE
 There is considerable geographical
and environmental influences in
incidence.
 The incidence is higher in eastern than
western countries. Its incidence in
India is 1:160 and 1:2000 in UK.
Hydatidiform Mole
 Incidence:
 In the United States,
 1in 600 therapeutic abortions
 1 in 1,500 pregnancies
 Internationally:
 In Japan & China, 1-2 in 1,000 pregnancies
 In Indonesia & India, 12 in 1,000 pregnancies
 In the United Arab of Emirates,
 2 in 1000 deliveries (population-based study; Graham IH,
Fajardo AM; 1988)
 In Saudi Arabia;
 1.48 in 1000 live births (hospital-based study; Felemban AA,
et al; 1969)
In the United States,
•1in 600
therapeutic
abortions
•1 in 1,500
pregnancies
In Asian countries,
•The rate is 10 times
higher than in
Europe and North
America
In Saudi Arabia;,
•1.48 in 1000 live births
(hospital-based study;
Felemban AA, et al;
1969)
Contd…….
 It is prevalent among teenage and elderly
patient with high parity.
TYPES
1. COMPLETE
2. PARTIAL
Complete mole
 A complete mole is caused by a single
sperm combining with an egg which has
lost its DNA.
 The genotype is typically 46XX due to
subsequent mitosis of fertilizing sperm but
can also be 46XY.
Partial mole
 Partial mole occurs when an egg is
fertilized by 2 sperm or by ,sperm which
reduplicates itself yielding the genotype of
69 XXY or 92XXXY
Hydatidiform mole
Complete mole Partial mole Partial mole
Partial mol ( fetal tissue)
Grossly placenta a mixture of normal and
hydropic villi
Fetus Severe growth restriction
Multiple congenital anomalies
Risk Factors hydatidiform
mole
 Strongest risk factors are
Age and a history of prior hydatidiform
mole
 Both extremes of reproductive age
adolescents twofold risk
Older than 40 tenfold risk
 History of Prior mole
 High parity
 Disturbed maternal immune mechanism
suggested by:
 Rise in gammaglobulin level in absence of
hepatic disease
 Increased association with AB blood group
which possess no ABO antibody
 An ethnic predisposition
 Diet (Deficiencies of protein or)
(Vitamin A deficiency)
 Animal fat
 Smoking
 Increased paternal age
 The risk of another mole
 Complete mole is 1.5 percent
 Partial mole is 2.7 percent
Two prior molar pregnancies
 the risk is 23 percent
Pathogenesis and Cytogenetics of HM
Genetic
Constituti
on
Diploid Triploid/ teraploid
Patho-
genesis
4%
Fertilization
of an empty
ovum by two
sperms
“Diandric
dispermy”
90%
Triploid
fertilization of
a normal
ovum by two
sperms
“Dispermic
triploidy”
96%
Fertilization
of an empty
ovum by one
sperms that
undergoes
duplication
“Diandric
diploidy”
10%
Tetraploid
fertilization of a
normal ovum
by three
sperms
“Dispermi
c triploidy”
Karyotype46XX
69XXX
69YXX
69YYX
46XX
46XY
Complete Partial
Complete Mole, Pathogenesis
Duplication 46XX
Empty ovum
23X
Diandric diploidy
Androgenesis
Paternal
chromosomes only
Complete Mole, Pathogenesis
46XX
Empty ovum
23X
Dispermic diploidy
Paternal
chromosomes only
23X 23X
23X
Partial Mole, Pathogenesis
69XXY
Normal ovum
23X
Dispermic triploidy
Paternal extra set
23Y 23X
23Y 23X
23X
Hydatidiform Mole
Alterations in gene
expression profiles
Up-regulation and down-regulation of
proteins committed to cell growth
control
e.g. Up-regulation of growth
factor and cytokine mediated
pathways, and antiapoptosis
genes
Trophoblastic hyperplasia
e.g. Down-regulation of insulin
growth factor binding proteins
and tumor necrosis factor
receptor
Pathogenesis
 Principally a disease of the chorion
 Death of the ovum ir failure of the embryo
to grow is essential to develop complete H.
mole
 The secretion from the hyperplastic cells
and transferred substances from the
maternal blood accumulates in the stroma
of the villi which are deviod of blood
vessels
 This results in distension of the villi to
form small vesicles
 The distension may also be due to edema
and liquification of the stroma
 Vesicle fluid is interstitial fluid and is
almost similar to ascitic or edema fluid but
rich in hCG
Naked eye appearance
 The mass filling the uterus is made of
multiple chains and clusters of cysts of
varying sizes
 No trace of embryo or the amniotic sac
 Hemorrhage, if occurs, takes place in the
decidual space
Microscopic appearance
 Marked prolifiration of syncitial and
cytotrophoblastic epithelium
 Marked thining of the sromal tissue due to
hydropoc degeneration
 Absence of blood vessels
FEATURES COMPLETE
MOLE
PARTIAL MOLE
karyotype 46XX, paternal Triploid or quadriploid
Embryo/fetus absent Present
Villious edema All villi Some villi
Trophoblastic
proliferation
Diffuse, circumferential Focal, slight
Uterine size More than the date Less than the date
Beta hCG High(>50000) Slight elevation
Behaviour 2% choriocarcinoma Rare
Clinical features
 Amenorrhea 8-12 weeks with following
manifestation
 Vaginal bleeding
 Varying degree of abdominal pain
 Constitutional symptoms
 Patient become sick without any apparent reason
 Vomiting of pregnancy becomes excessive
 Breathlessness
 Thyrotoxic symptoms
 Expulsion of grape like vesicles per
vaginum
 History of quickening absent
Clinical Presentation:
Complete mole:
Vaginal
bleeding
Severe
anemia
Passage of
hydropic
villi
Signs
 Features suggestive of early pregnancy
 Pallor
 Features of pre-eclampsia
 Per abdomen
 Uterus –more than gestational period (70%)
 Uterus feels firm elastic(doughy )
 Fetal parts not palpable
 Absence of fetal movement and FHS
Vaginal examination
 Internal ballotement cannot be elicited
 Unilaternal or bilaternal enlargement of
ovary (25-50%)
 Finding of vesicles in the vaginal discharge
 Open cervical os
Classical symptom of a complete
mole
 Abnormal vaginal bleeding
 Lower abdominal pain
 Hyperemesis gravidarum
 Features of early onset of pre-eclampsia
 Uterus > dates
 No fetal parts and FHS
Classical symptoms
contd….
 Expulsion of vesicular tissues
 Theca lutein cyst of ovaries
 Hyperthyriodism
 Serum hCG >1,00,000 IU/ml
 USG –snow strom appearance
Hydatidiform Mole
 Diagnosis:
 History
 Clinical examination
 Ultrasound examination
 Serum hCG levels
 Histopathological examination
 Cytogenetic and molecular biological
examination
Hydatidiform Mole
 Diagnosis:
 Ultrasonography:
* The diagnosis of molar pregnancy is nearly always
made by ultrasonography
Complete mole
•The classical finding is a
“snow storm" pattern
•Theca lutein cysts are frequent
findings on ultrasound
The snow storm appearance of complete hydatidiform mole
Theca lutein cysts, a frequent finding on ultrasound
Hydatidiform Mole
 Diagnosis:
 Ultrasonography:
Partial mole
Abnormal gestational sac
The classic vesicular sonographic
findings of a complete mole are
usually not seen
Focal sonographic cystic changes
and/or hydropic changes in the
placenta are significantly associated
with the diagnosis of a partial molar
pregnancy
Hydatidiform Mole
 Diagnosis:
 Ultrasonography:
 However, based on ultrasound, correct diagnosis
can be suspected in only:
• 84% of patients with complete mole and
• 30% of patients with partial mole
(Lindholm and Flam, 1999)
 The accuracy of ultrasonogrophy is gestational age
dependent
In comlete mole:
• 100% of cases cane be diagnosed at a gestational age of
13 weeks or more
• 50% of cases cane be diagnosed in earlier pregnancies
(Lazarus et al, 1999)
Hydatidiform Mole
 Diagnosis:
 Serum hCG levels:
 Serum hCG levels of greater than 92 000 IU/l
associated with absent fetal heart beat indicate a
diagnosis of complete hydatidiform moles
(Romero et al, 1985)
 Serum hCG level decreases quickly if the patient
has an abortion, but it does not in molar pregnancy
Hydatidiform Mole
 Diagnosis:
 Histopathological examination:
 It should always be done as far as possible and
samples should be kept for DNA analysis for a
final diagnosis when histology can not
differentiate molar pregnancy from abortion
Table3: Pathological features of complete and partial
hydatidiform mole
Complete Mole Partial Mole
Macro-
scopically
A mass of large,
edematous villi that are
diffusely distributed,
typically described as
resembling a cluster of
grapes
The placental tissue is
less bulky
A few enlarged villi with
a focal distribution
A fetus may be
identified grossly that
often has multiple
congenital anomalies
including syndactyly of
the fingers & toes
The grape like vesicles in gross appearance
Table3: Pathological features of complete and partial
hydatidiform mole
Complete Mole Partial Mole
Micro-
scopicall
y
Enlarged edematous
villi which show a
central acellular fluid-
filled space referred to
as a “central cistern”
Abnormal
trophoblastic
proliferation that is
circumferential in
contrast to normal villi
in which trophoblastic
proliferation is at one
end of the villus
Absence of fetal tissue
Two distinct populations
of villi. One with large,
edematous villi with
central cisterns. The other
contains small villi that
show some degree of
stromal fibrosis
Abnormal circumferential
trophoblastic proliferation
Fetal tissue, RBSs
DIFFERENTIAL DIAGNOSIS
1. THREATENED ABORTION
2. FIBROID OR OVARIAN TUMOR WITH
PREGNANCY.
3. MULTIPLE PREGNANCY
4. MISTAKEN DATE
5. ACUTE HYDRAMINOS
 Complications associated with molar
pregnacy:
 Those related to the increased trophoblastic
tissue volume:
 Theca-lutein cysts
 Pregnancy-induced hypertension,
 hyperthyroidism,
 Respiratory distress
 Hyperemesis
 Those related to its management:
 Uterine perforation
Hydatidiform Mole, complications
 Theca-lutein cysts:
 Prevalence:
 Clinically evident theca lutein cysts (usually >5–6 cm) are
detected in about 25-35% of women with molar pregnancies
 Association:
 They usually correlate with marked elevation of serum hCG
levels above 100,000 IU/l
 Complications:
 Pain or pressure that may require percutaneous aspirations.
 Torsion, rupture, or bleeding are rare complications that can
require oophorectomy
 Bilateral theca letein cysts increase the risk of post-molar GTD
 Course:
 The mean time for theca luteal cysts to regress is approximately
8 weeks
Hydatidiform Mole, complications
 Respiratory distress syndrome:
 Prevalence:
 Rare
 Pathophysiology:
 Embolization of trophoblastic tissue
 Transient impairment of left ventricular function
during induction of anesthesia for suction D&C of
molar pregnancy
 coexisting conditions such as anemia,
hyperthyroidism, hypertension from preeclampsia
 Risk factors:
 Uterine size larger than 14 to 16 weeks’
 High levels of hCG
Hydatidiform Mole, complications
 Respiratory distress syndrome:
 Presentation:
 Tachypnia and tachycardia following evacuation
 Bilateral pulmonary infiltrates on chest x-ray
 Management:
 Central venous monitoring
 Ventilatory support
 Course:
 It should resolve within 24 to 48 hours after molar
evacuation
Hydatidiform Mole, complications
 Hyperthyroidism:
 Prevalence:
 Clinical hyperthyroidism is seen in less than 10%
of patients with molar pregnancies
 A small number of patients may have elevated
thyroid function tests without clinical evidence of
disease
 Management:
 Beta-blockers should be administered prior to
molar evacuation to prevent thyroid storm that may
be induced by anesthesia and surgery.
 A hydatidiform mole and a co-existent fetus:
 Prevalence:
 Rare (1 in 22,000–100,000)
 partial moles and twin gestations with co-existent fetuses
and molar gestations
 Diagnosis:
 Usually, by ultrasound
 Few, after examination of the placenta following delivery
 Complications:
 Increased risk of medical complications
 Increased risk for postmolar gestational trophoblastic disease
 Management:
 No clear guidelines for management
 Risk Factors for post-molar gestational trophoblastic
disease:
 Advanced maternal age
 Factors that reflect the volume of trophoblastic tissue:Clinical
factors that are associated with
 high hCG levels (>100,000 mIU/mL)
 uterus large for date,
 bilateral theca lutein cysts,
 Respiratory distress syndrome after molar evacuation,
 eclampsia,
 hyperthyroidism,
 Uterine subinvolution with post evacuation hemorrhage.
(With any one of these factors or a combination of many, the risk of
post-molar GTD has ranges from 25% to 100%)
Hydatidiform Mole
 Risk Factors for post-molar gestational trophoblastic disease:
 The presence of “invasive trophoblast antigen (ITA)”
which has 100% sensitivity and specificity for invasive
trophoblastic tumors
(Cole et la, 2003)
*There is no correlation between the degree of anaplasia and
the risk of post-molar GTD
COMPLICATIONS
 IMMEDIATE
1. Hemorrhage and shock
2. Sepsis
3. Perforation of uterus
4. Pre-eclampsia
5. Acute pulmonary insufficiency
6. Coagulation failure
 LATE
Development of choriocarcinoma (2 to 20%)
Risk factors of malignant change:
 Patient’s age>40 or <20
 Parity >3
 Serum hCG> 100000 mIU/mL
 Uterine size> 20 wk
 Previous history of molar pregnancy
 Thece leutin cysts: large(>6cm diameter)
MANAGEMENT
 The principle of the management:
1. Suction evacuation of the uterus
2. Supportive therapy
3. Counselling for regular follow up
The patient are grouped into two:
 Group A:the mole is in the process of
expulsion
 Group B:the uterus remains inert
Management
Complete history and physical examination
Investigations
Medical and surgical care
1
3
2
 History and physcal examination:
 Should aim to rule out the classic symptoms and
signs that would lead to a diagnosis of:
 severe anemia
 dehydration
 preeclampsia
 thyrotoxicosis
The patient should be stabilized hemodynamically
 Management:
 Investigations:
 Laboratory:
 Pre-evacuation hCG
 Complete blood count
 Electrolytes, BUN, creatinine
 Liver function tests
 Thyroid function tests
 Imaging:
 Pelvic ultrasound
 Chest x-ray
Hydatidiform Mole
 Management:
 Medical care:
 Correction of:
 Anemia
 Dehydration
 Hyperthyroidism
 hypertension
Management:Surgical
Suction curettage
(with oxytocin or
prostaglandin
infusion)
Hysterectomy
•The method of choice
•Increased risk of
medical complications
•Associated with a
markedly decreased rate
of malignant sequelae
(3.5%) when compared
with suction evacuation.
Hysterectomy
Hysterectomy: is indicated in:
a)Patient with over 35,
b)Patient complete her family
irrespective of age,
c)Uncontrolled hemorrhage or
perforation during surgical evacuation,
Counselling
Counselling for follow up:
Routine follow up is mandatory for
all cases for at least 1 year.
Intervals: initially the check up must be made
at an interval of 1 week till the serum hCG
levels become negative.This usually happen
by 4-8 weeks.
once negative within 56 days,the patient
is followed up at every 1 month intervals
for 6 months.
Women undergone chemotherapy should be
followed up for 1 year after hCG has
been normal.
Methods employed in each visit:
a)enquire about each symptoms
b)abdomino vaginal examination
c)investigations:hCG,chest x-ray
PROPHYLACTIC
CHEMOTHERAPY
 If the hCG levels fails to normal by
the stipulated time(10-12) weeks or
relevation at 4-8 weeks.
 Post evacuation hemorrhage.
 Where follow up facilities are not
adequate.
 Evidence of metastasis irrespective of
the level of hCG.
 Prophylactic Chemotherapy:
 In one randomized clinical trial, a single
course of methotrexate and folinic acid
reduced the incidence of postmolar
trophoblastic disease from 47.4% to
14.3% (P <.05) in patients with high-risk
moles:
hCG levels greater than 100,000
mIU/mL,
uterine size greater than gestational age,
ovarian size greater than 6 cm),
 However, the incidence was not reduced in
patients with low-risk moles
 On the other hand, the use or prophylactic
chemotherapy increases the risk of drug resistance
 Because of the excellent primary cure rates among
women with post-molar GTD, and mortality
achieved by monitoring patients with serial hCG
determinations and instituting chemotherapy only
in patients with postmolar gestational
trophoblastic disease outweighs the potential risk
and small benefit of routine prophylactic
chemotherapy.
Pregnancy after Hydatidiform Mole:
 Risk of another molar pregnancy:
 Increased by 10-fold (1–2% incidence)
 Current recommendations for management of
subsequent pregnancies:
 an early ultrasound to confirm normal gestational
development and dates
 A chest x-ray to screen for occult metastasis
masked by the hCG rise of pregnancy
 Examination of the placenta or products of
conception histologically at the time of delivery or
evacuation for evidence of occult trophoblastic
disease
 An hCG level should be obtained 6 weeks post
evacuation or delivery to confirm normalization.
CONTRACEPTIVE ADVICE
 The patient is advised not to be
pregnant for at least 1 year.
 Use of contraception
IUD is contraindicated.
OCP:after hCG value have been
normal.
Barrier method.
Hydatidiform Mole
 Prognosis:
 Post-molar gestational trophoblastic disease:
 Risk:
 Following complete mole: 20%
 Following partial mole: 5%
 Type:
 70% to 90% are persistent or invasive moles
 10% to 30% are choriocarcinomas
 Diagnosis:
 A rising, plateauing, or persistent elevation of human chorionic
gonadotropin after evacuation of a hydatidiform mole or an
ectopic or term pregnancy
PROGNOSIS
 More than 80% of H. moles are benign. The
outcome after treatment is usually excellent.
Highly effective means of contraception are
recommended to avoid pregnancy for at least 6 to
12 months.
 About 15 to 20% of cases may develop into
persistent GTD.
 In 2 to 10% of cases it may change into
choriocarcinoma.
 Over 90% of women with malignant, non
spreading cancer are able to survive and retain
their ability to conceive and bear children.
 In those with metastatic cancer, remission
remains at 75 to 85%, although their childbearing
ability is usually lost.
NURSING DIAGNOSIS
 Acute pain related to uterine contraction.
 Risk for fluid volume deficit related to
execessive vascular loss.
 Ineffective uteroplacental tissue perfusion
related to abnormal trophoblastic
proliferation.
 Risk for maternal injury related to blood
loss,abnormal blood profile,impaired immune
system.
 Fear related to fetal loss and outcome
of pregnancy.
Molar pregnancy
Molar pregnancy

More Related Content

What's hot (20)

Preterm Premature Rupture Of Membranes (PPROM)
Preterm Premature Rupture Of Membranes (PPROM)Preterm Premature Rupture Of Membranes (PPROM)
Preterm Premature Rupture Of Membranes (PPROM)
 
gestational trophoblastic disease GTD
gestational trophoblastic disease GTDgestational trophoblastic disease GTD
gestational trophoblastic disease GTD
 
Inversion Of Uterus
Inversion Of UterusInversion Of Uterus
Inversion Of Uterus
 
Rh iso immunization
Rh  iso immunization Rh  iso immunization
Rh iso immunization
 
Induction of labor
Induction of laborInduction of labor
Induction of labor
 
Rupture of the uterus
Rupture of the uterusRupture of the uterus
Rupture of the uterus
 
Dysfunctional uterine bleeding
Dysfunctional uterine bleedingDysfunctional uterine bleeding
Dysfunctional uterine bleeding
 
management of placenta previa
management of placenta previamanagement of placenta previa
management of placenta previa
 
Intrauterine fetal death
Intrauterine fetal death Intrauterine fetal death
Intrauterine fetal death
 
Miscarriages
MiscarriagesMiscarriages
Miscarriages
 
Obstructed labour
Obstructed labourObstructed labour
Obstructed labour
 
Molar pregnancy
Molar pregnancyMolar pregnancy
Molar pregnancy
 
Placenta praevia
Placenta praeviaPlacenta praevia
Placenta praevia
 
pre eclampsia
pre eclampsiapre eclampsia
pre eclampsia
 
Breech presentation
Breech presentationBreech presentation
Breech presentation
 
Postmenopausal bleeding for undergraduate
Postmenopausal bleeding for undergraduatePostmenopausal bleeding for undergraduate
Postmenopausal bleeding for undergraduate
 
Instrumental vaginaldelivery...
Instrumental  vaginaldelivery...Instrumental  vaginaldelivery...
Instrumental vaginaldelivery...
 
Puerperal Pyrexia
Puerperal PyrexiaPuerperal Pyrexia
Puerperal Pyrexia
 
Ovarian cysts
Ovarian cystsOvarian cysts
Ovarian cysts
 
Polyhydramios
PolyhydramiosPolyhydramios
Polyhydramios
 

Viewers also liked

Molar pregnancy
Molar pregnancyMolar pregnancy
Molar pregnancyradionadia
 
Gestational Trophoblastic Disease - www.jinekolojivegebelik.com
Gestational Trophoblastic Disease - www.jinekolojivegebelik.comGestational Trophoblastic Disease - www.jinekolojivegebelik.com
Gestational Trophoblastic Disease - www.jinekolojivegebelik.comjinekolojivegebelik.com
 
Hydatidiform mole
Hydatidiform moleHydatidiform mole
Hydatidiform moleGio Arki
 
Depression in reproductive age women
Depression in reproductive age womenDepression in reproductive age women
Depression in reproductive age womenNirsuba Gurung
 
Physiological jaundice
Physiological jaundicePhysiological jaundice
Physiological jaundiceNirsuba Gurung
 
Hydatidiform (vesicular) mole
Hydatidiform (vesicular) moleHydatidiform (vesicular) mole
Hydatidiform (vesicular) moleraj kumar
 
Gestational trophoblastic disease ( Molar pregnancy )
Gestational trophoblastic disease ( Molar pregnancy )Gestational trophoblastic disease ( Molar pregnancy )
Gestational trophoblastic disease ( Molar pregnancy )Mohammed Barznji
 
Anaesthetic considerations in cardiac patients undergoing non
Anaesthetic considerations in cardiac patients undergoing nonAnaesthetic considerations in cardiac patients undergoing non
Anaesthetic considerations in cardiac patients undergoing nonomar143
 

Viewers also liked (20)

Molar Pregnancy
Molar PregnancyMolar Pregnancy
Molar Pregnancy
 
Molar pregnancy
Molar pregnancyMolar pregnancy
Molar pregnancy
 
Gestational Trophoblastic Disease - www.jinekolojivegebelik.com
Gestational Trophoblastic Disease - www.jinekolojivegebelik.comGestational Trophoblastic Disease - www.jinekolojivegebelik.com
Gestational Trophoblastic Disease - www.jinekolojivegebelik.com
 
Molar pregnancy
Molar pregnancyMolar pregnancy
Molar pregnancy
 
Gestational diabetes
Gestational diabetesGestational diabetes
Gestational diabetes
 
Molar pregnancy
Molar pregnancyMolar pregnancy
Molar pregnancy
 
Hydatidiform mole
Hydatidiform moleHydatidiform mole
Hydatidiform mole
 
Obstructed labor
Obstructed laborObstructed labor
Obstructed labor
 
Normal labour
Normal labourNormal labour
Normal labour
 
Gestational trophoblastic-diseases(molar pregnancy)
Gestational trophoblastic-diseases(molar pregnancy)Gestational trophoblastic-diseases(molar pregnancy)
Gestational trophoblastic-diseases(molar pregnancy)
 
Depression in reproductive age women
Depression in reproductive age womenDepression in reproductive age women
Depression in reproductive age women
 
Vital sign assessment
Vital sign assessmentVital sign assessment
Vital sign assessment
 
Cardiotocography
CardiotocographyCardiotocography
Cardiotocography
 
Physiological jaundice
Physiological jaundicePhysiological jaundice
Physiological jaundice
 
Hydrops
HydropsHydrops
Hydrops
 
Hydatidiform (vesicular) mole
Hydatidiform (vesicular) moleHydatidiform (vesicular) mole
Hydatidiform (vesicular) mole
 
Gestational trophoblastic disease ( Molar pregnancy )
Gestational trophoblastic disease ( Molar pregnancy )Gestational trophoblastic disease ( Molar pregnancy )
Gestational trophoblastic disease ( Molar pregnancy )
 
Vesicular mole for undergraduate
Vesicular mole for undergraduateVesicular mole for undergraduate
Vesicular mole for undergraduate
 
Gestational Trophoblastic disease
Gestational Trophoblastic diseaseGestational Trophoblastic disease
Gestational Trophoblastic disease
 
Anaesthetic considerations in cardiac patients undergoing non
Anaesthetic considerations in cardiac patients undergoing nonAnaesthetic considerations in cardiac patients undergoing non
Anaesthetic considerations in cardiac patients undergoing non
 

Similar to Molar pregnancy

Seminar on gestational trophoblastic disease (gtd) (f inal)
Seminar on gestational trophoblastic disease (gtd) (f inal)Seminar on gestational trophoblastic disease (gtd) (f inal)
Seminar on gestational trophoblastic disease (gtd) (f inal)Santosh Narayankar
 
molar for class.pptx
molar for class.pptxmolar for class.pptx
molar for class.pptxiceatashna
 
molar for class.pptx
molar for class.pptxmolar for class.pptx
molar for class.pptxiceatashna
 
Hydatidiform Mole.pptx
Hydatidiform Mole.pptxHydatidiform Mole.pptx
Hydatidiform Mole.pptxEdwardOwillah
 
Gestational trophoblastic disease
Gestational trophoblastic diseaseGestational trophoblastic disease
Gestational trophoblastic diseasepriya saxena
 
choriocarcinoma ppt.pptx
choriocarcinoma ppt.pptxchoriocarcinoma ppt.pptx
choriocarcinoma ppt.pptxPoonamJhamb3
 
Gtd mola hidatidosa
Gtd mola hidatidosaGtd mola hidatidosa
Gtd mola hidatidosaTrigunawan
 
Gestational trophoblastic disease (GTD).pptx
Gestational trophoblastic disease  (GTD).pptxGestational trophoblastic disease  (GTD).pptx
Gestational trophoblastic disease (GTD).pptxJwan AlSofi
 
Class first molar pregnancy
Class first molar pregnancyClass first molar pregnancy
Class first molar pregnancyramajoshi7
 
Gynecology 5th year, 5th & 6th lectures (Dr. Muhabat Salih Saeid)
Gynecology 5th year, 5th & 6th lectures (Dr. Muhabat Salih Saeid)Gynecology 5th year, 5th & 6th lectures (Dr. Muhabat Salih Saeid)
Gynecology 5th year, 5th & 6th lectures (Dr. Muhabat Salih Saeid)College of Medicine, Sulaymaniyah
 
molarpregnancy-190830175936 (1).pptx
molarpregnancy-190830175936 (1).pptxmolarpregnancy-190830175936 (1).pptx
molarpregnancy-190830175936 (1).pptxFatimaMalazai1
 
2. ECTOPIC & MOLAR PREGNANCY.pptx
2. ECTOPIC & MOLAR PREGNANCY.pptx2. ECTOPIC & MOLAR PREGNANCY.pptx
2. ECTOPIC & MOLAR PREGNANCY.pptxMaximilianTUNGARAZA
 
Hydatidiform Mole.pptx.pptx
Hydatidiform Mole.pptx.pptxHydatidiform Mole.pptx.pptx
Hydatidiform Mole.pptx.pptxrachnajaju
 
HYDATIDIFORM MOLE: APPROACH AND MANAGEMENT
HYDATIDIFORM MOLE: APPROACH AND MANAGEMENTHYDATIDIFORM MOLE: APPROACH AND MANAGEMENT
HYDATIDIFORM MOLE: APPROACH AND MANAGEMENTSharad Dahal
 

Similar to Molar pregnancy (20)

Hydatid form mole
Hydatid form moleHydatid form mole
Hydatid form mole
 
Seminar on gestational trophoblastic disease (gtd) (f inal)
Seminar on gestational trophoblastic disease (gtd) (f inal)Seminar on gestational trophoblastic disease (gtd) (f inal)
Seminar on gestational trophoblastic disease (gtd) (f inal)
 
molar for class.pptx
molar for class.pptxmolar for class.pptx
molar for class.pptx
 
molar for class.pptx
molar for class.pptxmolar for class.pptx
molar for class.pptx
 
Hydatidiform Mole.pptx
Hydatidiform Mole.pptxHydatidiform Mole.pptx
Hydatidiform Mole.pptx
 
Gestational trophoblastic disease
Gestational trophoblastic diseaseGestational trophoblastic disease
Gestational trophoblastic disease
 
choriocarcinoma ppt.pptx
choriocarcinoma ppt.pptxchoriocarcinoma ppt.pptx
choriocarcinoma ppt.pptx
 
G tt d up to date (1)
G tt d up to date (1)G tt d up to date (1)
G tt d up to date (1)
 
Gtd mola hidatidosa
Gtd mola hidatidosaGtd mola hidatidosa
Gtd mola hidatidosa
 
Hydatidiform mole/ VESICULAR MOLE
Hydatidiform mole/ VESICULAR MOLEHydatidiform mole/ VESICULAR MOLE
Hydatidiform mole/ VESICULAR MOLE
 
Gestational trophoblastic disease (GTD).pptx
Gestational trophoblastic disease  (GTD).pptxGestational trophoblastic disease  (GTD).pptx
Gestational trophoblastic disease (GTD).pptx
 
vesicular molle 2
vesicular molle 2vesicular molle 2
vesicular molle 2
 
Class first molar pregnancy
Class first molar pregnancyClass first molar pregnancy
Class first molar pregnancy
 
Gynecology 5th year, 5th & 6th lectures (Dr. Muhabat Salih Saeid)
Gynecology 5th year, 5th & 6th lectures (Dr. Muhabat Salih Saeid)Gynecology 5th year, 5th & 6th lectures (Dr. Muhabat Salih Saeid)
Gynecology 5th year, 5th & 6th lectures (Dr. Muhabat Salih Saeid)
 
molarpregnancy-190830175936 (1).pptx
molarpregnancy-190830175936 (1).pptxmolarpregnancy-190830175936 (1).pptx
molarpregnancy-190830175936 (1).pptx
 
fgtfgjjg.pptx
fgtfgjjg.pptxfgtfgjjg.pptx
fgtfgjjg.pptx
 
Hydatidiform mole
Hydatidiform moleHydatidiform mole
Hydatidiform mole
 
2. ECTOPIC & MOLAR PREGNANCY.pptx
2. ECTOPIC & MOLAR PREGNANCY.pptx2. ECTOPIC & MOLAR PREGNANCY.pptx
2. ECTOPIC & MOLAR PREGNANCY.pptx
 
Hydatidiform Mole.pptx.pptx
Hydatidiform Mole.pptx.pptxHydatidiform Mole.pptx.pptx
Hydatidiform Mole.pptx.pptx
 
HYDATIDIFORM MOLE: APPROACH AND MANAGEMENT
HYDATIDIFORM MOLE: APPROACH AND MANAGEMENTHYDATIDIFORM MOLE: APPROACH AND MANAGEMENT
HYDATIDIFORM MOLE: APPROACH AND MANAGEMENT
 

More from Nirsuba Gurung

More from Nirsuba Gurung (7)

Abruptio placenta
Abruptio placentaAbruptio placenta
Abruptio placenta
 
Retained placenta
Retained  placentaRetained  placenta
Retained placenta
 
Abnormal uterine contraction
Abnormal uterine contraction Abnormal uterine contraction
Abnormal uterine contraction
 
Health education
Health education Health education
Health education
 
1st stage managment
1st stage managment1st stage managment
1st stage managment
 
Quality assurance in nursing
Quality assurance in nursingQuality assurance in nursing
Quality assurance in nursing
 
Types of evaluation tool
Types of evaluation toolTypes of evaluation tool
Types of evaluation tool
 

Recently uploaded

PHYSIOTHERAPY IN HEART TRANSPLANTATION..
PHYSIOTHERAPY IN HEART TRANSPLANTATION..PHYSIOTHERAPY IN HEART TRANSPLANTATION..
PHYSIOTHERAPY IN HEART TRANSPLANTATION..AneriPatwari
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Classmanuelazg2001
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfSasikiranMarri
 
Role of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdfRole of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdfDivya Kanojiya
 
Plant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdfPlant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdfDivya Kanojiya
 
Phytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfPhytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfDivya Kanojiya
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranTara Rajendran
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfSreeja Cherukuru
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!ibtesaam huma
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...MehranMouzam
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)MohamadAlhes
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
 
World-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptxWorld-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptxEx WHO/USAID
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxKezaiah S
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdfDolisha Warbi
 
SHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptxSHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptxAbhishek943418
 

Recently uploaded (20)

PHYSIOTHERAPY IN HEART TRANSPLANTATION..
PHYSIOTHERAPY IN HEART TRANSPLANTATION..PHYSIOTHERAPY IN HEART TRANSPLANTATION..
PHYSIOTHERAPY IN HEART TRANSPLANTATION..
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Class
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
 
Role of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdfRole of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdf
 
Plant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdfPlant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdf
 
Phytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfPhytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdf
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
 
World-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptxWorld-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptx
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptx
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
 
SHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptxSHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptx
 

Molar pregnancy

  • 1.
  • 2. Molar pregnancy Presented By Nirsuba Gurung Masters in nursing Women health and development
  • 3.  Gestational Trophoblastic disease comprises a spectrum of interrelated conditions originating from the placenta.
  • 4.  Gestational trophoblastic disease is a prolifirative disorder of trophoblastic cells  It can be benign, premalignant or malignant
  • 5. Classification of gestational Trophoblastic disease WHO Classification Malignant neoplasms of various types of trophoblats Malformations of the chorionic villi that are predisposed to develop trophoblastic malignacies Benign entities that can be confused with with these other lesions Choriocarcinoma Complete Hydatidiform moles Placental site nodule Exaggerated placental s Epithilioid trophoblastic tumors Placental site trophoblastic tumor Partial Invasive
  • 6.  Non-metastatic disease: confined to the uterus  Metastatic  A- low risk-good prognosis  B – high risk-poor prognosis
  • 7. Low risk  Disease present in less than 4 mooths duration  Initial serum hCG level < 40,000 IU/ml  Metastasis limited to lung and vagina  No prior chemotherapy  No preceding term pregnancy
  • 8. High risk  Long duration of disease  Initial serum hCG level > 40,000 IU/ml  Brain or liver metastasis  Failure of prior chemotherapy  Following term pregnancy
  • 9.
  • 10. Hydatidiform Mole  Definition:  In latin "hydatid" means "drop of water” "mole" means "spot”  Pathologically, Hydatidiform moles represents placentas with abnormally developed chorionic villi (enlarged, edematous and vesicular villi with variable amounts of proliferative trophoblast)
  • 11.
  • 12. Macroscopic of Hydatidiform mole Hydropic villi Grapelike vesicles filled clear material usually 1 to 3cm diameter proliferation of the trophoblast
  • 13. Hydatidiform mole(molar pregnancy)  Molar pregnancy is an abnormal form of pregnancy, wherein a non viable , fertilized egg implants in the uterus, and thereby converts pregnancy process into pathological ones.  It is characterized by presence of hyadatidiform moles.
  • 14. It is an abnormal condition of the placenta where there are partly degenerative and partly proliferative changes in the young chorionic villi.
  • 15.  These results in the formation of clusters of small cysts of varying size  It is regarded as a begin neoplasia of the chorion with malignant potential
  • 16. INCIDENCE  There is considerable geographical and environmental influences in incidence.  The incidence is higher in eastern than western countries. Its incidence in India is 1:160 and 1:2000 in UK.
  • 17. Hydatidiform Mole  Incidence:  In the United States,  1in 600 therapeutic abortions  1 in 1,500 pregnancies  Internationally:  In Japan & China, 1-2 in 1,000 pregnancies  In Indonesia & India, 12 in 1,000 pregnancies  In the United Arab of Emirates,  2 in 1000 deliveries (population-based study; Graham IH, Fajardo AM; 1988)  In Saudi Arabia;  1.48 in 1000 live births (hospital-based study; Felemban AA, et al; 1969)
  • 18. In the United States, •1in 600 therapeutic abortions •1 in 1,500 pregnancies In Asian countries, •The rate is 10 times higher than in Europe and North America In Saudi Arabia;, •1.48 in 1000 live births (hospital-based study; Felemban AA, et al; 1969)
  • 19. Contd…….  It is prevalent among teenage and elderly patient with high parity.
  • 21. Complete mole  A complete mole is caused by a single sperm combining with an egg which has lost its DNA.  The genotype is typically 46XX due to subsequent mitosis of fertilizing sperm but can also be 46XY.
  • 22. Partial mole  Partial mole occurs when an egg is fertilized by 2 sperm or by ,sperm which reduplicates itself yielding the genotype of 69 XXY or 92XXXY
  • 23. Hydatidiform mole Complete mole Partial mole Partial mole Partial mol ( fetal tissue) Grossly placenta a mixture of normal and hydropic villi Fetus Severe growth restriction Multiple congenital anomalies
  • 24. Risk Factors hydatidiform mole  Strongest risk factors are Age and a history of prior hydatidiform mole  Both extremes of reproductive age adolescents twofold risk Older than 40 tenfold risk
  • 25.  History of Prior mole  High parity  Disturbed maternal immune mechanism suggested by:  Rise in gammaglobulin level in absence of hepatic disease  Increased association with AB blood group which possess no ABO antibody
  • 26.  An ethnic predisposition  Diet (Deficiencies of protein or) (Vitamin A deficiency)  Animal fat  Smoking  Increased paternal age
  • 27.  The risk of another mole  Complete mole is 1.5 percent  Partial mole is 2.7 percent Two prior molar pregnancies  the risk is 23 percent
  • 28. Pathogenesis and Cytogenetics of HM Genetic Constituti on Diploid Triploid/ teraploid Patho- genesis 4% Fertilization of an empty ovum by two sperms “Diandric dispermy” 90% Triploid fertilization of a normal ovum by two sperms “Dispermic triploidy” 96% Fertilization of an empty ovum by one sperms that undergoes duplication “Diandric diploidy” 10% Tetraploid fertilization of a normal ovum by three sperms “Dispermi c triploidy” Karyotype46XX 69XXX 69YXX 69YYX 46XX 46XY Complete Partial
  • 29. Complete Mole, Pathogenesis Duplication 46XX Empty ovum 23X Diandric diploidy Androgenesis Paternal chromosomes only
  • 30. Complete Mole, Pathogenesis 46XX Empty ovum 23X Dispermic diploidy Paternal chromosomes only 23X 23X 23X
  • 31. Partial Mole, Pathogenesis 69XXY Normal ovum 23X Dispermic triploidy Paternal extra set 23Y 23X 23Y 23X 23X
  • 32. Hydatidiform Mole Alterations in gene expression profiles Up-regulation and down-regulation of proteins committed to cell growth control e.g. Up-regulation of growth factor and cytokine mediated pathways, and antiapoptosis genes Trophoblastic hyperplasia e.g. Down-regulation of insulin growth factor binding proteins and tumor necrosis factor receptor
  • 33. Pathogenesis  Principally a disease of the chorion  Death of the ovum ir failure of the embryo to grow is essential to develop complete H. mole  The secretion from the hyperplastic cells and transferred substances from the maternal blood accumulates in the stroma of the villi which are deviod of blood vessels
  • 34.  This results in distension of the villi to form small vesicles  The distension may also be due to edema and liquification of the stroma  Vesicle fluid is interstitial fluid and is almost similar to ascitic or edema fluid but rich in hCG
  • 35. Naked eye appearance  The mass filling the uterus is made of multiple chains and clusters of cysts of varying sizes  No trace of embryo or the amniotic sac  Hemorrhage, if occurs, takes place in the decidual space
  • 36.
  • 37. Microscopic appearance  Marked prolifiration of syncitial and cytotrophoblastic epithelium  Marked thining of the sromal tissue due to hydropoc degeneration  Absence of blood vessels
  • 38. FEATURES COMPLETE MOLE PARTIAL MOLE karyotype 46XX, paternal Triploid or quadriploid Embryo/fetus absent Present Villious edema All villi Some villi Trophoblastic proliferation Diffuse, circumferential Focal, slight Uterine size More than the date Less than the date Beta hCG High(>50000) Slight elevation Behaviour 2% choriocarcinoma Rare
  • 39. Clinical features  Amenorrhea 8-12 weeks with following manifestation  Vaginal bleeding  Varying degree of abdominal pain  Constitutional symptoms  Patient become sick without any apparent reason  Vomiting of pregnancy becomes excessive  Breathlessness  Thyrotoxic symptoms
  • 40.  Expulsion of grape like vesicles per vaginum  History of quickening absent
  • 42. Signs  Features suggestive of early pregnancy  Pallor  Features of pre-eclampsia  Per abdomen  Uterus –more than gestational period (70%)  Uterus feels firm elastic(doughy )  Fetal parts not palpable  Absence of fetal movement and FHS
  • 43. Vaginal examination  Internal ballotement cannot be elicited  Unilaternal or bilaternal enlargement of ovary (25-50%)  Finding of vesicles in the vaginal discharge  Open cervical os
  • 44. Classical symptom of a complete mole  Abnormal vaginal bleeding  Lower abdominal pain  Hyperemesis gravidarum  Features of early onset of pre-eclampsia  Uterus > dates  No fetal parts and FHS
  • 45. Classical symptoms contd….  Expulsion of vesicular tissues  Theca lutein cyst of ovaries  Hyperthyriodism  Serum hCG >1,00,000 IU/ml  USG –snow strom appearance
  • 46. Hydatidiform Mole  Diagnosis:  History  Clinical examination  Ultrasound examination  Serum hCG levels  Histopathological examination  Cytogenetic and molecular biological examination
  • 47. Hydatidiform Mole  Diagnosis:  Ultrasonography: * The diagnosis of molar pregnancy is nearly always made by ultrasonography Complete mole •The classical finding is a “snow storm" pattern •Theca lutein cysts are frequent findings on ultrasound
  • 48. The snow storm appearance of complete hydatidiform mole
  • 49. Theca lutein cysts, a frequent finding on ultrasound
  • 50. Hydatidiform Mole  Diagnosis:  Ultrasonography: Partial mole Abnormal gestational sac The classic vesicular sonographic findings of a complete mole are usually not seen Focal sonographic cystic changes and/or hydropic changes in the placenta are significantly associated with the diagnosis of a partial molar pregnancy
  • 51. Hydatidiform Mole  Diagnosis:  Ultrasonography:  However, based on ultrasound, correct diagnosis can be suspected in only: • 84% of patients with complete mole and • 30% of patients with partial mole (Lindholm and Flam, 1999)  The accuracy of ultrasonogrophy is gestational age dependent In comlete mole: • 100% of cases cane be diagnosed at a gestational age of 13 weeks or more • 50% of cases cane be diagnosed in earlier pregnancies (Lazarus et al, 1999)
  • 52. Hydatidiform Mole  Diagnosis:  Serum hCG levels:  Serum hCG levels of greater than 92 000 IU/l associated with absent fetal heart beat indicate a diagnosis of complete hydatidiform moles (Romero et al, 1985)  Serum hCG level decreases quickly if the patient has an abortion, but it does not in molar pregnancy
  • 53. Hydatidiform Mole  Diagnosis:  Histopathological examination:  It should always be done as far as possible and samples should be kept for DNA analysis for a final diagnosis when histology can not differentiate molar pregnancy from abortion
  • 54. Table3: Pathological features of complete and partial hydatidiform mole Complete Mole Partial Mole Macro- scopically A mass of large, edematous villi that are diffusely distributed, typically described as resembling a cluster of grapes The placental tissue is less bulky A few enlarged villi with a focal distribution A fetus may be identified grossly that often has multiple congenital anomalies including syndactyly of the fingers & toes
  • 55. The grape like vesicles in gross appearance
  • 56. Table3: Pathological features of complete and partial hydatidiform mole Complete Mole Partial Mole Micro- scopicall y Enlarged edematous villi which show a central acellular fluid- filled space referred to as a “central cistern” Abnormal trophoblastic proliferation that is circumferential in contrast to normal villi in which trophoblastic proliferation is at one end of the villus Absence of fetal tissue Two distinct populations of villi. One with large, edematous villi with central cisterns. The other contains small villi that show some degree of stromal fibrosis Abnormal circumferential trophoblastic proliferation Fetal tissue, RBSs
  • 57. DIFFERENTIAL DIAGNOSIS 1. THREATENED ABORTION 2. FIBROID OR OVARIAN TUMOR WITH PREGNANCY. 3. MULTIPLE PREGNANCY 4. MISTAKEN DATE 5. ACUTE HYDRAMINOS
  • 58.  Complications associated with molar pregnacy:  Those related to the increased trophoblastic tissue volume:  Theca-lutein cysts  Pregnancy-induced hypertension,  hyperthyroidism,  Respiratory distress  Hyperemesis  Those related to its management:  Uterine perforation
  • 59. Hydatidiform Mole, complications  Theca-lutein cysts:  Prevalence:  Clinically evident theca lutein cysts (usually >5–6 cm) are detected in about 25-35% of women with molar pregnancies  Association:  They usually correlate with marked elevation of serum hCG levels above 100,000 IU/l  Complications:  Pain or pressure that may require percutaneous aspirations.  Torsion, rupture, or bleeding are rare complications that can require oophorectomy  Bilateral theca letein cysts increase the risk of post-molar GTD  Course:  The mean time for theca luteal cysts to regress is approximately 8 weeks
  • 60. Hydatidiform Mole, complications  Respiratory distress syndrome:  Prevalence:  Rare  Pathophysiology:  Embolization of trophoblastic tissue  Transient impairment of left ventricular function during induction of anesthesia for suction D&C of molar pregnancy  coexisting conditions such as anemia, hyperthyroidism, hypertension from preeclampsia  Risk factors:  Uterine size larger than 14 to 16 weeks’  High levels of hCG
  • 61. Hydatidiform Mole, complications  Respiratory distress syndrome:  Presentation:  Tachypnia and tachycardia following evacuation  Bilateral pulmonary infiltrates on chest x-ray  Management:  Central venous monitoring  Ventilatory support  Course:  It should resolve within 24 to 48 hours after molar evacuation
  • 62. Hydatidiform Mole, complications  Hyperthyroidism:  Prevalence:  Clinical hyperthyroidism is seen in less than 10% of patients with molar pregnancies  A small number of patients may have elevated thyroid function tests without clinical evidence of disease  Management:  Beta-blockers should be administered prior to molar evacuation to prevent thyroid storm that may be induced by anesthesia and surgery.
  • 63.  A hydatidiform mole and a co-existent fetus:  Prevalence:  Rare (1 in 22,000–100,000)  partial moles and twin gestations with co-existent fetuses and molar gestations  Diagnosis:  Usually, by ultrasound  Few, after examination of the placenta following delivery  Complications:  Increased risk of medical complications  Increased risk for postmolar gestational trophoblastic disease  Management:  No clear guidelines for management
  • 64.  Risk Factors for post-molar gestational trophoblastic disease:  Advanced maternal age  Factors that reflect the volume of trophoblastic tissue:Clinical factors that are associated with  high hCG levels (>100,000 mIU/mL)  uterus large for date,  bilateral theca lutein cysts,  Respiratory distress syndrome after molar evacuation,  eclampsia,  hyperthyroidism,  Uterine subinvolution with post evacuation hemorrhage. (With any one of these factors or a combination of many, the risk of post-molar GTD has ranges from 25% to 100%)
  • 65. Hydatidiform Mole  Risk Factors for post-molar gestational trophoblastic disease:  The presence of “invasive trophoblast antigen (ITA)” which has 100% sensitivity and specificity for invasive trophoblastic tumors (Cole et la, 2003) *There is no correlation between the degree of anaplasia and the risk of post-molar GTD
  • 66. COMPLICATIONS  IMMEDIATE 1. Hemorrhage and shock 2. Sepsis 3. Perforation of uterus 4. Pre-eclampsia 5. Acute pulmonary insufficiency 6. Coagulation failure
  • 67.  LATE Development of choriocarcinoma (2 to 20%) Risk factors of malignant change:  Patient’s age>40 or <20  Parity >3  Serum hCG> 100000 mIU/mL  Uterine size> 20 wk  Previous history of molar pregnancy  Thece leutin cysts: large(>6cm diameter)
  • 68. MANAGEMENT  The principle of the management: 1. Suction evacuation of the uterus 2. Supportive therapy 3. Counselling for regular follow up
  • 69. The patient are grouped into two:  Group A:the mole is in the process of expulsion  Group B:the uterus remains inert
  • 70. Management Complete history and physical examination Investigations Medical and surgical care 1 3 2
  • 71.  History and physcal examination:  Should aim to rule out the classic symptoms and signs that would lead to a diagnosis of:  severe anemia  dehydration  preeclampsia  thyrotoxicosis The patient should be stabilized hemodynamically
  • 72.  Management:  Investigations:  Laboratory:  Pre-evacuation hCG  Complete blood count  Electrolytes, BUN, creatinine  Liver function tests  Thyroid function tests  Imaging:  Pelvic ultrasound  Chest x-ray
  • 73. Hydatidiform Mole  Management:  Medical care:  Correction of:  Anemia  Dehydration  Hyperthyroidism  hypertension
  • 74. Management:Surgical Suction curettage (with oxytocin or prostaglandin infusion) Hysterectomy •The method of choice •Increased risk of medical complications •Associated with a markedly decreased rate of malignant sequelae (3.5%) when compared with suction evacuation.
  • 75. Hysterectomy Hysterectomy: is indicated in: a)Patient with over 35, b)Patient complete her family irrespective of age, c)Uncontrolled hemorrhage or perforation during surgical evacuation,
  • 76. Counselling Counselling for follow up: Routine follow up is mandatory for all cases for at least 1 year. Intervals: initially the check up must be made at an interval of 1 week till the serum hCG levels become negative.This usually happen by 4-8 weeks. once negative within 56 days,the patient is followed up at every 1 month intervals for 6 months.
  • 77. Women undergone chemotherapy should be followed up for 1 year after hCG has been normal. Methods employed in each visit: a)enquire about each symptoms b)abdomino vaginal examination c)investigations:hCG,chest x-ray
  • 78. PROPHYLACTIC CHEMOTHERAPY  If the hCG levels fails to normal by the stipulated time(10-12) weeks or relevation at 4-8 weeks.  Post evacuation hemorrhage.  Where follow up facilities are not adequate.  Evidence of metastasis irrespective of the level of hCG.
  • 79.  Prophylactic Chemotherapy:  In one randomized clinical trial, a single course of methotrexate and folinic acid reduced the incidence of postmolar trophoblastic disease from 47.4% to 14.3% (P <.05) in patients with high-risk moles: hCG levels greater than 100,000 mIU/mL, uterine size greater than gestational age, ovarian size greater than 6 cm),
  • 80.  However, the incidence was not reduced in patients with low-risk moles  On the other hand, the use or prophylactic chemotherapy increases the risk of drug resistance  Because of the excellent primary cure rates among women with post-molar GTD, and mortality achieved by monitoring patients with serial hCG determinations and instituting chemotherapy only in patients with postmolar gestational trophoblastic disease outweighs the potential risk and small benefit of routine prophylactic chemotherapy.
  • 81. Pregnancy after Hydatidiform Mole:  Risk of another molar pregnancy:  Increased by 10-fold (1–2% incidence)  Current recommendations for management of subsequent pregnancies:  an early ultrasound to confirm normal gestational development and dates  A chest x-ray to screen for occult metastasis masked by the hCG rise of pregnancy  Examination of the placenta or products of conception histologically at the time of delivery or evacuation for evidence of occult trophoblastic disease  An hCG level should be obtained 6 weeks post evacuation or delivery to confirm normalization.
  • 82. CONTRACEPTIVE ADVICE  The patient is advised not to be pregnant for at least 1 year.  Use of contraception IUD is contraindicated. OCP:after hCG value have been normal. Barrier method.
  • 83. Hydatidiform Mole  Prognosis:  Post-molar gestational trophoblastic disease:  Risk:  Following complete mole: 20%  Following partial mole: 5%  Type:  70% to 90% are persistent or invasive moles  10% to 30% are choriocarcinomas  Diagnosis:  A rising, plateauing, or persistent elevation of human chorionic gonadotropin after evacuation of a hydatidiform mole or an ectopic or term pregnancy
  • 84. PROGNOSIS  More than 80% of H. moles are benign. The outcome after treatment is usually excellent. Highly effective means of contraception are recommended to avoid pregnancy for at least 6 to 12 months.  About 15 to 20% of cases may develop into persistent GTD.  In 2 to 10% of cases it may change into choriocarcinoma.
  • 85.  Over 90% of women with malignant, non spreading cancer are able to survive and retain their ability to conceive and bear children.  In those with metastatic cancer, remission remains at 75 to 85%, although their childbearing ability is usually lost.
  • 86. NURSING DIAGNOSIS  Acute pain related to uterine contraction.  Risk for fluid volume deficit related to execessive vascular loss.  Ineffective uteroplacental tissue perfusion related to abnormal trophoblastic proliferation.  Risk for maternal injury related to blood loss,abnormal blood profile,impaired immune system.
  • 87.  Fear related to fetal loss and outcome of pregnancy.